US FDA approves updated COVID vaccines for 2026-27 season

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/27/2026

1. NVDA
2. OKTA
3. CRM
4. CRWD
5. VEEV
6. P
7. KKR
8. HPQ
9. NTNX
10. SPY

August 27, 2026 5:48 PM EDT

A child receives a dose of the Moderna coronavirus disease (COVID-19) vaccine at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S. September 11, 2025. REUTERS/Hannah Beier

Aug 27 (Reuters) - ‌The U.S. ​Food ​and Drug Administration approved Moderna, Novavax-Sanofi and Pfizer-BioNTech's updated COVID ‌vaccines, the companies said on Thursday, ⁠after an advisory panel recommended that the ‌shots should target ‌the dominant XFG variant.

• Four COVID shots had been approved for use ​in the United States: Moderna's mNEXSPIKE and Spikevax, Pfizer-BioNTech's, Comirnaty — all ⁠three mRNA-based vaccines — and Novavax-Sanofi's, protein-based shot that ​takes longer to manufacture.

• All manufacturers previously said they could make ​the updated shot in ‌time for the 2026-27 immunization season.

• In May, eight ⁠of the committee's nine experts voted in favor of targeting the XFG variant ⁠for the 2026-27 campaign.

• For the 2025-26 season, ​the FDA had recommended COVID shots target LP.8.1 — a subvariant of the JN.1 strain.

• ‌According to the Centers for Disease Control and Prevention's COVID ‌dashboard, new data on strains ⁠is currently unavailable ‌due to low ​sequencing submissions.

(Reporting by Christy Santhosh in Bengaluru; Editing by Joyjeet ‌Das)


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters

Related Entities

FDA